Primary prevention of cardiovascular disease in women

References

• Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982–3021. doi: 10.1016/j.jacc.2020.11.010.
   PubMed Web of Science ®Google Scholar
• Vogel B, Acevedo M, Appelman Y, et al. The Lancet women and cardiovascular disease commission: reducing the global burden by 2030. Lancet. 2021;397(10292):2385–2438. doi: 10.1016/S0140-6736(21)00684-X.
   PubMed Web of Science ®Google Scholar
• Enserro DM, Vasan RS, Xanthakis V. Twenty-year trends in the American Heart Association cardiovascular health score and impact on subclinical and clinical cardiovascular disease: the Framingham offspring study. J Am Heart Assoc. 2018;7(11):e008741. doi: 10.1161/jaha.118.008741.
   Web of Science ®Google Scholar
• Corlin L, Short MI, Vasan RS, et al. Association of the duration of ideal cardiovascular health through adulthood with cardiometabolic outcomes and mortality in the Framingham offspring study. JAMA Cardiol. 2020;5(5):549–556. doi: 10.1001/jamacardio.2020.0109.
   PubMed Web of Science ®Google Scholar
• Lopez AD, Adair T. Is the long-term decline in cardiovascular-disease mortality in high-income countries over? Evidence from national vital statistics. Int J Epidemiol. 2019;48(6):1815–1823. doi: 10.1093/ije/dyz143.
   PubMed Web of Science ®Google Scholar
• Hyun KK, Redfern J, Patel A, et al. Gender inequalities in cardiovascular risk factor assessment and management in primary healthcare. Heart. 2017;103(7):492–498. doi: 10.1136/heartjnl-2016-310216.
   PubMed Web of Science ®Google Scholar
• Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2224–2260. doi: 10.1016/S0140-6736(12)61766-8.
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. doi: 10.1016/S0140-6736(04)17018-9.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337. doi: 10.1093/eurheartj/ehab484.
   PubMed Web of Science ®Google Scholar
• Wright JTJr, Williamson JD, Whelton PK, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–2116. doi: 10.1056/NEJMoa1511939.
   PubMed Web of Science ®Google Scholar
• Gerdts E, Okin PM, de Simone G, et al. Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study. Hypertension. 2008;51(4):1109–1114. doi: 10.1161/hypertensionaha.107.107474.
   PubMed Web of Science ®Google Scholar
• Wenger NK, Arnold A, Bairey Merz CN, et al. Hypertension across a Woman’s Life Cycle. J Am Coll Cardiol. 2018;71(16):1797–1813. doi: 10.1016/j.jacc.2018.02.033.
   PubMed Web of Science ®Google Scholar
• Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336(7653):1121–1123. doi: 10.1136/bmj.39548.738368.BE.
   PubMed Web of Science ®Google Scholar
• Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338(may19 1):b1665–b1665. doi: 10.1136/bmj.b1665.
   PubMed Web of Science ®Google Scholar
• Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993;328(13):914–921. doi: 10.1056/nejm199304013281303.
   PubMed Web of Science ®Google Scholar
• Dickerson JE, Hingorani AD, Ashby MJ, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999;353(9169):2008–2013. doi: 10.1016/s0140-6736(98)07614-4.
   PubMed Web of Science ®Google Scholar
• Chow CK, Atkins ER, Hillis GS, et al. Initial treatment with a single pill containing quadruple combination of quarter doses of blood pressure medicines versus standard dose monotherapy in patients with hypertension (QUARTET): a phase 3, randomised, double-blind, active-controlled trial. Lancet. 2021;398(10305):1043–1052. doi: 10.1016/s0140-6736(21)01922-x.
   PubMed Web of Science ®Google Scholar
• Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–2472. doi: 10.1093/eurheartj/ehx144.
   PubMed Web of Science ®Google Scholar
• Ference BA, Robinson JG, Brook RD, et al. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med. 2016;375(22):2144–2153. doi: 10.1056/NEJMoa1604304.
   PubMed Web of Science ®Google Scholar
• Matthews KA, El Khoudary SR, Brooks MM, et al. Lipid changes around the final menstrual period predict carotid subclinical disease in postmenopausal women. Stroke. 2017;48(1):70–76. doi: 10.1161/strokeaha.116.014743.
   PubMed Web of Science ®Google Scholar
• Shepherd J. The West of Scotland Coronary Prevention Study: a trial of cholesterol reduction in Scottish men. Am J Cardiol. 1995;76(9):113C–117C. doi: 10.1016/s0002-9149(99)80480-9.
   PubMed Web of Science ®Google Scholar
• Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet. 2012;380(9841):581–590. doi: 10.1016/S0140-6736(12)60367-5.
   PubMed Web of Science ®Google Scholar
• Nanna MG, Wang TY, Xiang Q, et al. Sex differences in the use of statins in community practice. Circ Cardiovasc Qual Outcomes. 2019;12(8):e005562. doi: 10.1161/circoutcomes.118.005562.
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107(19):2409–2415. doi: 10.1161/01.CIR.0000068312.21969.C8.
   PubMed Web of Science ®Google Scholar
• Serban MC, Banach M, Mikhailidis DP. Clinical implications of the IMPROVE-IT trial in the light of current and future lipid-lowering treatment options. Expert Opin Pharmacother. 2016;17(3):369–380. doi: 10.1517/14656566.2016.1118055.
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Giugliano RP, Pedersen TR. Evolocumab in patients with cardiovascular disease. N Engl J Med. 2017;377(8):787–788. doi: 10.1056/NEJMc1708587.
   PubMedGoogle Scholar
• Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382(16):1507–1519. doi: 10.1056/NEJMoa1912387.
   PubMed Web of Science ®Google Scholar
• Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379(22):2097–2107. doi: 10.1056/NEJMoa1801174.
   PubMed Web of Science ®Google Scholar
• Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332(7533):73–78. doi: 10.1136/bmj.38678.389583.7C.
   PubMed Web of Science ®Google Scholar
• Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57(8):1542–1551. doi: 10.1007/s00125-014-3260-6.
   PubMed Web of Science ®Google Scholar
• de Jong M, Woodward M, Peters SAE. Diabetes, glycated hemoglobin, and the risk of myocardial infarction in women and men: a prospective cohort study of the UK biobank. Diabetes Care. 2020;43(9):2050–2059. doi: 10.2337/dc19-2363.
   PubMed Web of Science ®Google Scholar
• Carbone S, Dixon DL, Buckley LF, et al. Glucose-lowering therapies for cardiovascular risk reduction in type 2 diabetes mellitus: state-of-the-art review. Mayo Clin Proc. 2018;93(11):1629–1647. doi: 10.1016/j.mayocp.2018.07.018.
   PubMed Web of Science ®Google Scholar
• Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128. doi: 10.1056/NEJMoa1504720.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925.
   PubMed Web of Science ®Google Scholar
• Teo YH, Teo YN, Syn NL, et al. Effects of sodium/glucose cotransporter 2 (SGLT2) inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus: a systematic review and meta-analysis of randomized-controlled trials. J Am Heart Assoc. 2021;10(5):e019463. doi: 10.1161/JAHA.120.019463.
   PubMed Web of Science ®Google Scholar
• Sheahan KH, Wahlberg EA, Gilbert MP. An overview of GLP-1 agonists and recent cardiovascular outcomes trials. Postgrad Med J. 2020;96(1133):156–161. doi: 10.1136/postgradmedj-2019-137186.
   PubMed Web of Science ®Google Scholar
• Arnott C, Li Q, Kang A, et al. Sodium-glucose cotransporter 2 inhibition for the prevention of cardiovascular events in patients with type 2 diabetes mellitus: a systematic review and meta-analysis. J Am Heart Assoc. 2020;9(3):e014908. doi: 10.1161/JAHA.119.014908.
   PubMed Web of Science ®Google Scholar
• Singh AK, Singh R. Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials. Diabetes Metab Syndr. 2020;14(3):181–187. doi: 10.1016/j.dsx.2020.02.012.
   PubMed Web of Science ®Google Scholar
• Wright AK, Kontopantelis E, Emsley R, et al. Cardiovascular risk and risk factor management in type 2 diabetes mellitus. Circulation. 2019;139(24):2742–2753. doi: 10.1161/circulationaha.118.039100.
   PubMed Web of Science ®Google Scholar
• Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ. 2004;328(7455):1519. doi: 10.1136/bmj.38142.554479.AE.
   PubMed Web of Science ®Google Scholar
• Prescott E, Hippe M, Schnohr P, et al. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998;316(7137):1043–1047. doi: 10.1136/bmj.316.7137.1043.
   PubMedGoogle Scholar
• Messner B, Bernhard D. Smoking and cardiovascular disease: mechanisms of endothelial dysfunction and early atherogenesis. Arterioscler Thromb Vasc Biol. 2014;34(3):509–515. doi: 10.1161/ATVBAHA.113.300156.
   PubMed Web of Science ®Google Scholar
• GBD 2019 Tobacco Collaborators. Spatial, temporal, and demographic patterns in prevalence of smoking tobacco use and attributable disease burden in 204 countries and territories, 1990-2019: a systematic analysis from the Global Burden of Disease Study 2019. Lancet. 2021;397(10292):2337–2360. doi: 10.1016/s0140-6736(21)01169-7.
   PubMed Web of Science ®Google Scholar
• Piper ME, Smith SS, Schlam TR, et al. A randomized placebo-controlled clinical trial of 5 smoking cessation pharmacotherapies. Arch Gen Psychiatry. 2009;66(11):1253–1262. doi: 10.1001/archgenpsychiatry.2009.142.
   PubMed Web of Science ®Google Scholar
• Ma C, Avenell A, Bolland M, et al. Effects of weight loss interventions for adults who are obese on mortality, cardiovascular disease, and cancer: systematic review and meta-analysis. BMJ. 2017;359:j4849. doi: 10.1136/bmj.j4849.
   PubMed Web of Science ®Google Scholar
• Doumouras AG, Wong JA, Paterson JM, et al. Bariatric surgery and cardiovascular outcomes in patients with obesity and cardiovascular disease: a population-based retrospective cohort study. Circulation. 2021;143(15):1468–1480. doi: 10.1161/CIRCULATIONAHA.120.052386.
   PubMed Web of Science ®Google Scholar
• Moussa O, Ardissino M, Heaton T, et al. Effect of bariatric surgery on long-term cardiovascular outcomes: a nationwide nested cohort study. Eur Heart J. 2020;41(28):2660–2667. doi: 10.1093/eurheartj/ehaa069.
   PubMed Web of Science ®Google Scholar
• Gurtner HP. Pulmonale Hypertonie nach Appetizuglern [Pulmonary hypertension following appetite depressants]. Med Welt. 1972;23(29):1036–1041.
   PubMedGoogle Scholar
• Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337(9):581–588. doi: 10.1056/nejm199708283370901.
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi: 10.1056/NEJMoa1603827.
   PubMed Web of Science ®Google Scholar
• D’Agostino RBSr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117(6):743–753. doi: 10.1161/circulationaha.107.699579.
   PubMed Web of Science ®Google Scholar
• D’Agostino RBSr, Grundy S, Sullivan LM, et al. Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. Jama. 2001;286(2):180–187. doi: 10.1001/jama.286.2.180.
   PubMed Web of Science ®Google Scholar
• Hurley LP, Dickinson LM, Estacio RO, et al. Prediction of cardiovascular death in racial/ethnic minorities using Framingham risk factors. Circ Cardiovasc Qual Outcomes. 2010;3(2):181–187. doi: 10.1161/circoutcomes.108.831073.
   PubMed Web of Science ®Google Scholar
• Goff DCJr, Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49–S73. doi: 10.1161/01.cir.0000437741.48606.98.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Buring JE, Rifai N, et al. Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score. Jama. 2007;297(6):611–619. doi: 10.1001/jama.297.6.611.
   PubMed Web of Science ®Google Scholar
• Pylypchuk R, Wells S, Kerr A, et al. Cardiovascular disease risk prediction equations in 400 000 primary care patients in New Zealand: a derivation and validation study. Lancet. 2018;391(10133):1897–1907. doi: 10.1016/s0140-6736(18)30664-0.
   PubMed Web of Science ®Google Scholar
• SCORE Working Group and E. S. C. Cardiovascular Risk Collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439–2454. doi: 10.1093/eurheartj/ehab309.
   PubMed Web of Science ®Google Scholar
• Garcia M, Mulvagh SL, Merz CNB, et al. Cardiovascular disease in women: clinical perspectives. Circ Res. 2016;118(8):1273–1293. doi: 10.1161/CIRCRESAHA.116.307547.
   PubMed Web of Science ®Google Scholar
• Ngo AD, Roberts CL, Figtree G. Association between interpregnancy interval and future risk of maternal cardiovascular disease-a population-based record linkage study. BJOG. 2016;123(8):1311–1318. doi: 10.1111/1471-0528.13729.
   PubMed Web of Science ®Google Scholar
• El Khoudary SR, Aggarwal B, Beckie TM, et al. Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation. 2020;142(25):e506–e532. doi: 10.1161/cir.0000000000000912.
   PubMed Web of Science ®Google Scholar
• Janssen I, Powell LH, Crawford S, et al. Menopause and the metabolic syndrome: the Study of Women’s Health across the Nation. Arch Intern Med. 2008;168(14):1568–1575. doi: 10.1001/archinte.168.14.1568.
   PubMedGoogle Scholar
• Greendale GA, Sternfeld B, Huang M, et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019;4(5):e124865. doi: 10.1172/jci.insight.124865.
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018;39(34):3165–3241. doi: 10.1093/eurheartj/ehy340.
   PubMed Web of Science ®Google Scholar
• Durante A, Bronzato S. The increased cardiovascular risk in patients affected by autoimmune diseases: review of the various manifestations. J Clin Med Res. 2015;7(6):379–384. doi: 10.14740/jocmr2122w.
   PubMedGoogle Scholar
• Alexandre J, Cautela J, Ederhy S, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European Cardio-Oncology guidelines. J Am Heart Assoc. 2020;9(18):e018403. doi: 10.1161/JAHA.120.018403.
   PubMed Web of Science ®Google Scholar
• Backholer K, Peters SAE, Bots SH, et al. Sex differences in the relationship between socioeconomic status and cardiovascular disease: a systematic review and meta-analysis. J Epidemiol Commun Health. 2017;71(6):550–557. doi: 10.1136/jech-2016-207890.
   PubMed Web of Science ®Google Scholar
• Jenkins KR, Ofstedal MB. The association between socioeconomic status and cardiovascular risk factors among middle-aged and older men and women. Women Health. 2014;54(1):15–34. doi: 10.1080/03630242.2013.858098.
   PubMed Web of Science ®Google Scholar
• Rajan S, McKee M, Rangarajan S, et al. Association of symptoms of depression with cardiovascular disease and mortality in low-, middle-, and high-income countries. JAMA Psychiatry. 2020;77(10):1052–1063. doi: 10.1001/jamapsychiatry.2020.1351.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Carter JR, Bourjeily G. Cardiovascular disease in women across the lifespan: the importance of sleep. J Womens Health (Larchmt). 2020;29(3):452–460. doi: 10.1089/jwh.2020.8331.
   PubMed Web of Science ®Google Scholar
• St-Onge MP, Grandner MA, Brown D, et al. Sleep duration and quality: impact on lifestyle behaviors and cardiometabolic health: a scientific statement from the American Heart Association. Circulation. 2016;134(18):e367–e386. doi: 10.1161/CIR.0000000000000444.
   PubMed Web of Science ®Google Scholar
• Sands-Lincoln M, Loucks EB, Lu B, et al. Sleep duration, insomnia, and coronary heart disease among postmenopausal women in the women’s health initiative. J Womens Health (Larchmt). 2013;22(6):477–486. doi: 10.1089/jwh.2012.3918 23651054.
   PubMed Web of Science ®Google Scholar
• Butler MP, Emch JT, Rueschman M, et al. Apnea-hypopnea event duration predicts mortality in men and women in the sleep heart health study. Am J Respir Crit Care Med. 2019;199(7):903–912. doi: 10.1164/rccm.201804-0758OC.
   PubMed Web of Science ®Google Scholar
• Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. 2009;302(4):412–423. doi: 10.1001/jama.2009.1063.
   PubMed Web of Science ®Google Scholar
• Clarke R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med. 2009;361(26):2518–2528. doi: 10.1056/NEJMoa0902604.
   PubMed Web of Science ®Google Scholar
• Tsimikas S, Moriarty PM, Stroes ES. Emerging RNA therapeutics to lower blood levels of Lp(a). J Am Coll Cardiol. 2021;77(12):1576–1589. doi: 10.1016/j.jacc.2021.01.051.
   PubMed Web of Science ®Google Scholar
• Clouston SAP, Manganello JA, Richards M. A life course approach to health literacy: the role of gender, educational attainment and lifetime cognitive capability. Age Ageing. 2017;46(3):493–499. doi: 10.1093/ageing/afw229.
   PubMed Web of Science ®Google Scholar
• Kutner M, Greenberg E, Jin Y, et al. The health literacy of America’s adults: results from the 2003 National Assessment of Adult Literacy. Washington (DC): Education USDOE; 2006. p. 2006–2483.
   Google Scholar
• Al-Kindi SG, Brook RD, Biswal S, et al. Environmental determinants of cardiovascular disease: lessons learned from air pollution. Nat Rev Cardiol. 2020;17(10):656–672. doi: 10.1038/s41569-020-0371-2.
   PubMed Web of Science ®Google Scholar
• Wolf K, Hoffmann B, Andersen ZJ, et al. Long-term exposure to low-level ambient air pollution and incidence of stroke and coronary heart disease: a pooled analysis of six European cohorts within the ELAPSE project. Lancet Planet Health. 2021;5(9):e620–e632. doi: 10.1016/S2542-5196(21)00195-9.
   PubMedGoogle Scholar
• Bhatnagar A. Environmental determinants of cardiovascular disease. Circ Res. 2017;121(2):162–180. doi: 10.1161/CIRCRESAHA.117.306458.
   PubMed Web of Science ®Google Scholar
• Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary heart disease. Circulation. 2011;124(7):789–795. doi: 10.1161/CIRCULATIONAHA.110.010710.
   PubMed Web of Science ®Google Scholar
• 2018 Physical Activity Guidelines Advisory Committee. Physical activity guidelines advisory committee scientific report. Washington (DC): U.S. Department of Health and Human Services; 2018.
   Google Scholar
• Grace C, Begum R, Subhani S, et al. Prevention of type 2 diabetes in British Bangladeshis: qualitative study of community, religious, and professional perspectives. BMJ. 2008;337(v04 3):a1931–a1931. doi: 10.1136/bmj.a1931.
   PubMedGoogle Scholar
• Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. N Engl J Med. 2006;354(15):1601–1613. doi: 10.1056/NEJMra054035.
   PubMed Web of Science ®Google Scholar
• Wardle J, Haase AM, Steptoe A, et al. Gender differences in food choice: the contribution of health beliefs and dieting. Ann Behav Med. 2004;27(2):107–116. doi: 10.1207/s15324796abm2702_5.
   PubMed Web of Science ®Google Scholar
• Kiefer I, Rathmanner T, Kunze M. Eating and dieting differences in men and women. J Men’s Health Gender. 2005;2(2):194–201. doi: 10.1016/j.jmhg.2005.04.010.
   Google Scholar
• Pedersen SB, Jønler M, Richelsen B. Characterization of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab. 1994;78(6):1354–1359. doi: 10.1210/jcem.78.6.8200937.
   PubMed Web of Science ®Google Scholar
• Pant A, Gribbin S, McIntyre D, et al. Primary prevention of cardiovascular disease in women with a mediterranean diet: systematic review and meta-analysis. Heart. 2023;109(16):1208–1215. doi: 10.1136/heartjnl-2022-321930.
   PubMed Web of Science ®Google Scholar
• Vernon ST, Coffey S, D’Souza M, et al. ST-Segment-Elevation Myocardial Infarction (STEMI) patients without standard modifiable cardiovascular risk factors-how common are they, and what are their outcomes? J Am Heart Assoc. 2019;8(21):e013296. doi: 10.1161/jaha.119.013296.
   PubMed Web of Science ®Google Scholar
• Vernon ST, Coffey S, Bhindi R, et al. Increasing proportion of ST elevation myocardial infarction patients with coronary atherosclerosis poorly explained by standard modifiable risk factors. Eur J Prev Cardiol. 2017;24(17):1824–1830. doi: 10.1177/2047487317720287.
   PubMed Web of Science ®Google Scholar
• Figtree GA, Vernon ST, Hadziosmanovic N, et al. Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data. Lancet. 2021;397(10279):1085–1094. doi: 10.1016/S0140-6736(21)00272-5.
   PubMed Web of Science ®Google Scholar
• Lakoski SG, Greenland P, Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classified as “low risk” based on Framingham risk score: the multi-ethnic study of atherosclerosis (MESA). Arch Intern Med. 2007;167(22):2437–2442. doi: 10.1001/archinte.167.22.2437.
   PubMedGoogle Scholar
• Figtree GA, Vernon ST. Coronary artery disease patients without standard modifiable risk factors (SMuRFs) – a forgotten group calling out for new discoveries. Cardiovasc Res. 2021;117(6):e76–e78. doi: 10.1093/cvr/cvab145.
   PubMed Web of Science ®Google Scholar
• Gragnano F, Calabrò P. Role of dual lipid-lowering therapy in coronary atherosclerosis regression: Evidence from recent studies. Atherosclerosis. 2018;269:219–228. doi: 10.1016/j.atherosclerosis.2018.01.012.
   PubMed Web of Science ®Google Scholar
• Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66(5):495–507. doi: 10.1016/j.jacc.2015.05.065.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Puri R, Anderson T, et al. Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. Jama. 2016;316(22):2373–2384. doi: 10.1001/jama.2016.16951.
   PubMed Web of Science ®Google Scholar
• Rumberger JA, Schwartz RS, Simons DB, et al. Relation of coronary calcium determined by electron beam computed tomography and lumen narrowing determined by autopsy. Am J Cardiol. 1994;73(16):1169–1173. doi: 10.1016/0002-9149(94)90176-7.
   PubMed Web of Science ®Google Scholar
• Otsuka F, Sakakura K, Yahagi K, et al. Has our understanding of calcification in human coronary atherosclerosis progressed? Arterioscler Thromb Vasc Biol. 2014;34(4):724–736. doi: 10.1161/ATVBAHA.113.302642.
   PubMed Web of Science ®Google Scholar
• Agatston AS, Janowitz WR, Hildner FJ, et al. Quantification of coronary artery calcium using ultrafast computed tomography. J Am Coll Cardiol. 1990;15(4):827–832. doi: 10.1016/0735-1097(90)90282-t.
   PubMed Web of Science ®Google Scholar
• Mohlenkamp S, Lehmann N, Moebus S, et al. Quantification of coronary atherosclerosis and inflammation to predict coronary events and all-cause mortality. J Am Coll Cardiol. 2011;57(13):1455–1464. doi: 10.1016/j.jacc.2010.10.043.
   PubMed Web of Science ®Google Scholar
• Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol. 2016;67(2):139–147. doi: 10.1016/j.jacc.2015.10.058.
   PubMed Web of Science ®Google Scholar
• Kondos GT, Hoff JA, Sevrukov A, et al. Electron-beam tomography coronary artery calcium and cardiac events: a 37-month follow-up of 5635 initially asymptomatic low- to intermediate-risk adults. Circulation. 2003;107(20):2571–2576. doi: 10.1161/01.CIR.0000068341.61180.55.
   PubMed Web of Science ®Google Scholar
• Kelkar AA, Schultz WM, Khosa F, et al. Long-term prognosis after coronary artery calcium scoring among low-intermediate risk women and men. Circ Cardiovasc Imaging. 2016;9(4):e003742. doi: 10.1161/CIRCIMAGING.115.003742.
   PubMed Web of Science ®Google Scholar
• Inouye M, Abraham G, Nelson CP, et al. Genomic risk prediction of coronary artery disease in 480,000 adults: implications for primary prevention. J Am Coll Cardiol. 2018;72(16):1883–1893. doi: 10.1016/j.jacc.2018.07.079.
   PubMed Web of Science ®Google Scholar
• Dikilitas O, He B, Bailey K, et al. Association of polygenic risk scores with premature coronary heart disease: a comparative study. J Am Coll Cardiol. 2019;73(9):1793. doi: 10.1016/s0735-1097(19)32399-x.
   Web of Science ®Google Scholar
• Wünnemann F, Sin Lo K, Langford-Avelar A, et al. Validation of genome-wide polygenic risk scores for coronary artery disease in French Canadians. Circ Genom Precis Med. 2019;12(6):e002481. doi: 10.1161/circgen.119.002481.
   PubMed Web of Science ®Google Scholar
• Nicholls SJ, Vernon S, Figtree GA. Taking the next steps to implement polygenic risk scoring for improved risk stratification and primary prevention of coronary artery disease. Eur J Prev Cardiol. 2022;29(4):580–587. doi: 10.1093/eurjpc/zwaa030.
   PubMed Web of Science ®Google Scholar
• Vernon ST, Tang O, Kim T, et al. Metabolic signatures in coronary artery disease: results from the BioHEART-CT study. Cells. 2021;10(5):980. doi: 10.3390/cells10050980.
   PubMed Web of Science ®Google Scholar
• Kott KA, Vernon S, Hansen T, et al. Single-cell immune profiling in coronary artery disease: the role of state-of-the-art immunophenotyping with mass cytometry in the diagnosis of atherosclerosis. J Am Heart Assoc. 2020;9(24):e017759. doi: 10.1161/JAHA.120.017759.
   PubMed Web of Science ®Google Scholar
• Kott KA, Vernon ST, Hansen T, et al. Biobanking for discovery of novel cardiovascular biomarkers using imaging-quantified disease burden: protocol for the longitudinal, prospective, BioHEART-CT cohort study. BMJ Open. 2019;9(9):e028649. doi: 10.1136/bmjopen-2018-028649.
   PubMed Web of Science ®Google Scholar